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Abstract 
Background: As a surrogate marker of systemic inflammation, the lymphocyte‑to‑monocyte ratio (LMR) is an 
independent prognostic factor for various malignancies. This study investigated the prognostic significance of 
the pre‑chemotherapy LMR in patients with previously untreated metastatic colorectal cancer (mCRC) receiving 
chemotherapy.
Methods: The present study included newly diagnosed mCRC patients treated between January 2005 and Decem‑
ber 2013 with FOLFOX chemotherapy, specifically oxaliplatin 180 mg/m2 on day 1, with leucovorin 400 mg/m2 
administered as a 2‑hour infusion before the administration of 5‑fluorouracil 400 mg/m2 as an intravenous bolus 
injection, and 5‑fluorouracil 2400 mg/m2 as a 46‑h infusion immediately after 5‑fluorouracil bolus injection. The LMR 
was calculated as the absolute count of lymphocytes divided by the absolute count of monocytes. COX proportional 
hazards analysis was performed to evaluate the association of LMR with survival outcomes.
Results: A total of 488 patients were included. Patients with high pre‑chemotherapy LMR experienced signifi‑
cant improvements in progression‑free survival (PFS, 9.2 vs. 7.6 months, P < 0.001) and overall survival (OS, 19.4 vs. 
16.6 months, P < 0.001) compared with patients with low pre‑chemotherapy LMR. Subsequent COX multivariate 
analysis showed that high pre‑chemotherapy LMR (≥3.11) was an independent favorable prognostic factor for PFS 
and OS. Additionally, patients whose LMR remained high (high–high subgroup), increased (low–high subgroup), or 
decreased (high–low subgroup) following chemotherapy showed better results in terms of PFS and OS than patients 
whose LMR remained low (low–low subgroup) after chemotherapy.
Conclusions: For patients with previously untreated mCRC receiving FOLFOX chemotherapy, an elevated pre‑chem‑
otherapy LMR is an independent favorable prognostic factor for PFS and OS, and changes in the LMR before and after 
chemotherapy seem to predict the benefit of chemotherapy.
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Background
Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer among men and women in the most 
developed areas in China, and its incidence is increas-
ing significantly because of the aging population [1, 2]. 
Metastatic disease is found in approximately half of 
all patients [3]. Combined treatment with oxaliplatin 
(OHP) and 5-fluorouracil (5-FU) that is biochemically 
activated by leucovorin (LV), also known as FOLFOX 
regimen, remains the first-line treatment of metastatic 
colorectal cancer (mCRC) patients, with an objective 
response rate of 31% and a median survival of approxi-
mately 14  months [4, 5]. Due to unsatisfactory results 
obtained by palliative chemotherapy, identifying prog-
nostic and predictive biomarkers that can be used to 
improve disease management through patient classi-
fication remains the subject of intense investigation in 
mCRC.
Inflammation is a key component of the tumor micro-
environment [6]. Accumulating evidence has shed light 
on the molecular pathways that link inflammation and 
cancer, suggesting that inflammation in the tumor 
microenvironment leads to neoplastic cell proliferation, 
angiogenesis, metastasis, collapse of antitumor immu-
nity, and unresponsiveness to antineoplastic therapy 
[7–9]. Therefore, cancer-related inflammation repre-
sents a potential therapeutic target for treating cancer 
[10]. Lymphocytes can turn into tumor-infiltrating lym-
phocytes (TILs) by migrating into the tumor microenvi-
ronment. Stage III CRC patients with a high level of TILs 
experience better results in terms of 5-year overall sur-
vival (OS) and disease-free survival (DFS) than patients 
with a low level of TILs [11]. Monocytes can differentiate 
into macrophages in the tumor microenvironment. In 
turn, macrophages promote tumor cell migration, inva-
sion, and metastasis [12]. As a surrogate marker of sys-
temic inflammation, the lymphocyte-to-monocyte ratio 
(LMR) serves as an independent prognostic factor for a 
large variety of malignancies [13–16]. A study including 
372 patients with stages II and III colon cancer revealed 
that patients with preoperative LMR > 2.83 obtained sig-
nificant improvements in terms of time-to-recurrence 
and OS compared with patients with LMR ≤  2.83, and 
the benefit of adjuvant 5-FU-based chemotherapy was 
limited to patients with preoperative LMR > 2.83 [17].
To the best of our knowledge, the prognostic signifi-
cance of circulating LMR in patients with previously 
untreated mCRC receiving FOLFOX chemotherapy is 
not well defined. Therefore, this study investigated the 
prognostic significance of pre-chemotherapy LMR in 




This study was approved by the ethics committee of the 
Zhongshan Hospital of Sun Yat-sen University. Written 
informed consent was obtained from all patients prior to 
treatment.
Patient selection
Between January 2005 and December 2013, patients 
treated at the Zhongshan Hospital of Sun Yat-sen Uni-
versity were retrospectively identified to determine their 
eligibility for the study. The eligibility criteria were as 
follows: age ≥18 and ≤75  years, pathologically proven 
and chemotherapy-naïve mCRC, Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2, 
first-line chemotherapy with FOLFOX (OHP 180  mg/
m2 on day 1 with LV 400 mg/m2 administered as a 2-h 
infusion before 5-FU 400  mg/m2 administered as an 
intravenous bolus injection, and 5-FU 2400 mg/m2 as a 
46-h infusion immediately after 5-FU bolus injection), 
chemotherapy duration ≥6 and ≤12 cycles, and com-
plete clinical and follow-up data. Patients were excluded 
if they had any active infections prior to the first chemo-
therapy cycle.
Measurement of LMR
Peripheral blood was obtained within 3  days before 
the initiation of the first cycle of chemotherapy and 
between 3 and 4 weeks after the completion of the last 
cycle. A complete blood count with differential quan-
tification was generated using the automated hematol-
ogy analyzer Sysmex XE-2100 (Sysmex, Kobe, Japan). 
The LMR was calculated by dividing the absolute lym-
phocyte count (ALC) by the absolute monocyte count 
(AMC).
Statistical analysis
Progression-free survival (PFS) was calculated from the 
date of chemotherapy initiation to the date of first pro-
gression, death from any cause, or the last follow-up. 
OS was calculated from the time of diagnosis to the date 
of death from any cause. The optimal cutoff levels were 
determined by receiver operating curve (ROC) analysis. 
A Chi-square test was used to compare baseline features 
between different groups. Survival curves were generated 
using the Kaplan–Meier method and compared using 
the log-rank test. Univariate and multivariate analyses to 
determine prognostic predictors were performed using 
COX proportional hazard regression models. These anal-
yses were performed with SPSS software (version 16.0, 
SPSS Inc., Chicago, IL, USA). A two-tailed P < 0.05 was 
considered significant.
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Results
Patient characteristics
A total of 488 patients were eligible for the study. The 
median age at diagnosis was 54 years (range 37–72 years). 
The ratio of males to females was approximately 1.2:1. An 
ECOG performance status of less than 2 was observed 
in 314 patients (64.3%). Primary colon cancer was diag-
nosed in 259 patients (53.1%). The tumor was well or 
moderately differentiated in 283 patients (58.0%). The 
median number of metastatic sites was 2 (range 1–5). 
The median chemotherapy cycles were 9 (range 6–12). 
The median pre-chemotherapy lymphocyte and mono-
cyte counts were 2.83 × 109/L (range 0.31–5.64 × 109/L) 
and 0.65 × 109/L (range 0.16–4.19 × 109/L), respectively. 
All patients were followed up until December 31, 2014. 
The median follow-up time was 23.5  months (range 
4.3–32.8 months).
Selection of cut‑off values
Based on ROC curves for survival analysis, the optimal 
cut-off values were 2.70 ×  109/L for ALC, with an area 
under the curve (AUC) value of 0.634 [95% confidence 
interval (CI) 0.546–0.724, P  =  0.034]; 0.55  ×  109/L for 
AMC, with an AUC value of 0.712 (95% CI 0.613–0.795, 
P  =  0.008); and 3.11 for LMR, with an AUC value of 
0.733 (95% CI 0.638–0.786, P = 0.004).
Comparison of patient characteristics based on the cut‑off 
values
Of the 488 patients, 216 were assigned to the low-LMR 
(LMR < 3.11) group, and 272 were assigned to the high-
LMR (LMR  ≥  3.11) group. A comparison of the base-
line patient characteristics between high- and low-LMR 
groups is presented in Table 1. Both groups were well bal-
anced with respect to patient age, gender, and the site of 
primary tumor. However, significant differences between 
the low- and high-LMR groups were observed in terms 
of ECOG performance status, number of metastatic sites, 
differentiation, pre-chemotherapy ALC, and pre-chemo-
therapy AMC (all P < 0.05).
Survival outcomes
The median PFS and OS for all patients were 8.8 months 
(95% CI 8.4–9.2  months) and 18.2  months (95% CI 
17.5–18.9  months), respectively. Patients with a pre-
chemotherapy ALC of 2.70  ×  109/L or greater had 
longer, though not significantly longer, PFS [9.0 months 
(95% CI 8.6–9.4  months) vs. 8.2  months (95% CI 7.6–
8.8  months), P =  0.062; Fig.  1a] and OS [18.6  months 
(95% CI 17.9–19.3  months) vs. 17.8  months (95% CI 
16.6–19.0  months), P =  0.112; Fig.  1b] compared with 
patients with an ALC of less than 2.70 × 109/L. However, 
patients with a pre-chemotherapy AMC of less than 
0.55 ×  109/L had significantly longer PFS [9.4  months 
(95% CI 8.9–9.9  months) vs. 8.2  months (95% CI 7.7–
8.7  months), P  <  0.001; Fig.  1c] and OS [20.2  months 
(95% CI 18.7–21.7  months) vs. 17.4  months (95% CI 
16.3–18.5  months), P  <  0.001; Fig.  1d] than patients 
with an AMC of 0.55  ×  109/L or greater. In addition, 
patients in the high-LMR group experienced signifi-
cant improvements in PFS [9.2  months (95% CI 8.8–
9.6  months) vs. 7.6  months (95% CI 7.0–8.2  months), 
P  <  0.001; Fig.  1e] and OS [19.4  months (95% CI 
18.0–20.8  months) vs. 16.6  months (95% CI 15.3–
17.9 months), P < 0.001; Fig. 1f ] compared with patients 
in the low-LMR group.
Table 1 Comparison of  baseline clinical characteristics 
of  patients with  newly diagnosed metastatic colorectal 
cancer stratified by  pre-treatment lymphocyte-to-mono-
cyte ratio (LMR)
ALC absolute lymphocyte count, AMC absolute monocyte count, ECOG Eastern 
Cooperative Oncology Group







 Male 119 (55.1) 147 (54.0)
 Female 97 (44.9) 125 (46.0)
Age (years) 0.802
 <60 139 (64.4) 178 (65.4)
 ≥60 77 (35.6) 94 (34.6)
ECOG performance status 0.013
 <2 126 (58.3) 188 (69.1)
 ≥2 90 (41.7) 84 (30.9)
Site of primary tumor 0.907
 Colon 114 (52.8) 145 (53.3)
 Rectum 102 (47.2) 127 (46.7)
No. of metastatic sites <0.001
 ≤2 157 (72.7) 118 (43.4)
 >2 59 (27.3) 154 (56.6)
Tumor differentiation <0.001
 Well or moderate 163 (75.5) 120 (44.1)
 Poor 53 (24.5) 152 (55.9)
Pre‑chemotherapy ALC (×109/L)
 <2.70 122 (56.5) 107 (39.3)
 ≥2.70 94 (43.5) 165 (60.7)
Pre‑chemotherapy AMC (×109/L) <0.001
 <0.55 57 (26.4) 128 (47.1)
 ≥0.55 159 (73.6) 144 (52.9)
Page 4 of 9Lin et al. Chin J Cancer  (2016) 35:5 
Fig. 1 Kaplan–Meier estimates of progression‑free and overall survival of patients with newly diagnosed metastatic colorectal cancer stratified by 
pre‑treatment ALC (a, b), AMC (c, d), and LMR (e, f). ALC absolute lymphocyte count, AMC absolute monocyte count, LMR lymphocyte‑to‑monocyte 
ratio
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Univariate and multivariate analysis of pre‑chemotherapy 
LMR as a prognostic factor for PFS
Age, gender, ECOG performance status, site of pri-
mary tumor, number of metastatic sites, pre-chem-
otherapy ALC, AMC, and LMR were included in 
univariate and multivariate analyses. The univariate and 
multivariate analyses for PFS are shown in Table 2. Based 
on the univariate analysis, an ECOG performance sta-
tus of less than 2, no more than 2 metastatic sites, well 
or moderate differentiation, low pre-chemotherapy 
AMC (<0.55  ×  109/L), or high pre-chemotherapy LMR 
(≥3.11) were significantly associated with longer PFS (all 
P < 0.01). In the subsequent multivariate analysis, inde-
pendent unfavorable prognostic factors for PFS included 
a ECOG performance status of more than 2, more than 
2 metastatic sites, poor differentiation, and high pre-
chemotherapy AMC (all P  <  0.05), whereas only high 
pre-chemotherapy LMR was an independent favorable 
prognostic factor for PFS (P = 0.005).
Univariate and multivariate analyses of pre‑chemotherapy 
LMR as a prognostic factor for OS
The univariate and multivariate analyses for OS are sum-
marized in Table 3. The univariate analysis revealed that 
an ECOG performance status of less than 2, no more 
than 2 metastatic sites, well or moderate differentiation, 
low pre-chemotherapy AMC (<0.55  ×  109/L), or high 
pre-chemotherapy LMR (≥3.11) were significantly linked 
to a favorable OS. Subsequently, the multivariate analysis 
demonstrated that an ECOG performance status of more 
than 2, poor differentiation, and high pre-chemotherapy 
AMC were independent prognostic factors for shorter 
OS (all P < 0.01), whereas high pre-chemotherapy LMR 
(≥3.11) was an independent prognostic factor for longer 
OS (P = 0.004).
Changes in LMR and benefits of chemotherapy
The pretreatment low- and high-LMR groups were sub-
divided by the cut-off point of the post-chemotherapy 
LMR (3.11) as follows: low–low, low–high, high–low, and 
high–high. The changes in LMR and benefits of chemo-
therapy are listed in Table  4 and Fig.  2. Patients whose 
LMR remained high (high–high subgroup), increased 
(low–high subgroup), or decreased (high–low subgroup) 
after chemotherapy had significantly prolonged PFS and 
OS compared with patients whose LMR remained low 
(low–low subgroup).
Discussion
In the present study, patients with high pre-chemotherapy 
LMR experienced significant improvements in PFS (9.2 
vs. 7.6  months, P  <  0.001) and OS (19.4 vs. 16.6  months, 
P < 0.001) compared with patients with low pre-chemother-
apy LMR. Subsequent COX multivariate analysis showed 
that high pre-chemotherapy LMR (≥3.11) was an independ-
ent favorable prognostic factor for PFS and OS. Additionally, 
patients whose LMR remained high (high–high subgroup), 
increased (low–high subgroup), or decreased (high–low 
subgroup) following chemotherapy showed better results in 
terms of PFS and OS than patients whose LMR remained 
low (low–low subgroup) after chemotherapy, suggesting 
that the change in LMR before and after chemotherapy may 
predict the benefit of chemotherapy.
Table 2 Univariate and  multivariate analyses of  variables 
associated with  progression-free survival of  patients 
with newly diagnosed metastatic colorectal cancer
HR hazard ratio, CI confidential interval. Other abbreviations as in Table 1
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.931
 Male 1 (reference) 0.870 1 (reference)





 <65 1 (reference) 0.931 1 (reference)




ECOG performance status <0.001
 <2 1 (reference) 0.009 1 (reference)




Site of primary tumor 0.560
 Colon 1 (reference) 0.542 1 (reference)




No. of metastatic sites 0.049
 ≤2 1 (reference) 0.001 1 (reference)





 Well or moder‑
ate
1 (reference) <0.001 1 (reference)




Pre‑chemotherapy ALC (× 109/L) 0.059
 <2.70 1 (reference) 0.072 1 (reference)




Pre‑chemotherapy AMC (× 109/L) 0.001
 <0.55 1 (reference) 0.001 1 (reference)





 <3.11 1 (reference) <0.001 1 (reference)
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Approximately half of all CRC patients develop distant 
metastasis [3], which poses a huge clinical challenge. In 
clinical practice, the FOLFOX regimen is the treatment 
of choice for patients with chemotherapy-naïve mCRC 
and has favorable toxicity profiles compared with the 
irinotecan-based combination regimen [4, 5]. However, 
a significant difference in the response to chemothera-
peutic agents has been noted among mCRC patients, 
suggesting that mCRC is a heterogeneous disease. 
Hence, considerable strides have been made in seeking 
prognostic or predictive biomarkers to classify hetero-
geneous mCRC. Inflammation is profoundly involved in 
promoting pathogenesis and progression of tumor [6]. 
Nowacki et al. [18] revealed that a prolonged duration of 
ulcerative colitis dramatically increased the risk of CRC 
(P < 0.001), whereas the risk could be markedly reduced 
by anti-inflammatory treatment (P  <  0.02), suggesting 
that inflammation may have a profound influence on the 
pathogenesis of CRC. Lymphocytes play an important 
role in constraining the proliferation of malignant cells. 
As a surrogate marker of weak immunity, peripheral 
blood lymphopenia is associated with poor survival out-
comes in patients with nasopharyngeal carcinoma (NPC) 
[14]. TILs are observed in the tumor microenvironment 
and reflect an adaptive immune response [6]. The supe-
rior survival outcomes associated with high concentra-
tions of TILs in CRC has been well documented [19–21]. 
Furthermore, growing evidence suggests that CD8+ 
cells and other activated T lymphocytes might suppress 
metastasis rather than tumor growth [22]. Monocytes 
can differentiate into macrophages in the tumor micro-
environment [6]. Experimental evidence has shown 
remarkable interactions between tumor cells, mac-
rophages, and blood vessels, facilitating angiogenesis and 
promoting tumor cell motility, which eventually results in 
distant metastases [23, 24]. In addition, a survival advan-
tage associated with low levels of peripheral blood mono-
cytes has been observed in NPC patients [14]. Taking 
the above considerations into account, peripheral blood 
LMR, which is an indicator of systemic inflammation, 
becomes an ideal candidate due to the advantage of sim-
plicity, accessibility, and inexpensiveness compared with 
complex molecular markers.
A large cohort study including 1547 non-metastatic 
NPC patients showed that higher LMR levels (≥5.22) 
were significantly associated with longer DFS and OS 
(P  <  0.001) [14]. Subsequent multivariate COX propor-
tional hazard analysis confirmed that higher LMR lev-
els remained a significant independent factor for longer 
DFS (HR  =  0.669, 95% CI 0.535–0.838, P  <  0.001) and 
OS (HR  =  0.558, 95% CI 0.417–0.748, P  <  0.001) [14]. 
Lin et  al. [16] found that newly diagnosed metastatic 
non-small cell lung cancer patients with increased LMR 
(≥4.56) obtained longer PFS (5.60 vs. 5.04  months, 
P =  0.001) and OS (13.20 vs. 11.72  months, P  <  0.001) 
than those with decreased LMR. Moreover, LMR was 
an independent prognostic factor for PFS (HR =  0.660, 
95% CI 0.512–0.851, P  =  0.001) and OS (HR  =  0.530, 
95% CI 0.409––0.687, P < 0.001) [16]. For patients with 
stage II and III colon cancer, patients with high preopera-
tive LMR (>2.83) showed better results in terms of time-
to-recurrence (HR = 0.47, 95% CI 0.29–0.76, P = 0.002) 
and OS (HR = 0.51, 95% CI 0.31–0.83, P = 0.007) than 
Table 3 Univariate and  multivariate analyses of  variables 
associated with  overall survival of  patients with  newly 
diagnosed metastatic colorectal cancer
Abbreviations as in Tables 1 and 2
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.055 0.07
 Male 1 (reference) 1 (reference)




Age (years) 0.567 0.199
 <65 1 (reference) 1 (reference)




ECOG performance status 0.005 <0.001
 <2 1 (reference) 1 (reference)




Site of primary tumor 0.974 0.938
 Colon 1 (reference) 1 (reference)




No. of metastatic sites 0.002 0.065
 ≤2 1 (reference) 1 (reference)




Tumor differentiation <0.001 0.002
 Well or moder‑
ate
1 (reference) 1 (reference)




Pre‑chemotherapy ALC (×109/L) 0.121 0.391
 <2.70 1 (reference) 1 (reference)




Pre‑chemotherapy AMC (×109/L) <0.001 <0.001
 <0.55 1 (reference) 1 (reference)




Pre‑chemotherapy LMR <0.001 0.004
 <3.11 1 (reference) 1 (reference)
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those with low preoperative LMR [17]. Similar to these 
aforementioned reports, our study cohort demonstrated 
that chemotherapy-naïve mCRC patients with high pre-
chemotherapy LMR (≥3.11) showed significant improve-
ments in PFS (9.2 vs. 7.6 months, P < 0.001) and OS (19.4 
vs. 16.6 months, P < 0.001) compared with patients with 
low pre-chemotherapy LMR. Furthermore, our sub-
sequent COX multivariate analysis showed that high 
pre-chemotherapy LMR was an independent favorable 
prognostic factor for PFS (HR  =  0.710, 95% CI 0.558–
0.903; P =  0.005) and OS (HR =  0.662, 95% CI 0.501–
0.875, P =  0.004). Taking the above considerations into 
account, pre-treatment LMR seems to be an independent 
prognostic factor that can classify cancer patients into 
different prognostic subgroups, improving the personal-
ized management of cancer.
In addition to pre-treatment LMR, the prognostic sig-
nificance of changes in LMR before and after treatment 
should also be explored. In our study cohort, the optimal 
cut-off values of the pre- and post-chemotherapy LMR 
were both set at 3.11. Subsequently, all patients were 
divided into four subgroups based on the cut-off values 
of pre- and post-treatment LMRs. As expected, the low–
low subgroup had the worst survival results, whereas 
the high–high subgroup had the best survival results. 
Additionally, patients whose LMR increased (low–high 
subgroup) or decreased (high–low subgroup) after 
chemotherapy showed longer PFS and OS than patients 
Table 4 Changes in LMR and benefits of chemotherapy
Abbreviations as in Tables 1 and 2






Progression‑free survival (months) Overall survival (months)
Median (95% CI) HR (95% CI) P value Median (95% CI) HR (95% CI) P value*
Low–low 87 5.8 (5.1–6.5) 1 13.0 (10.3–15.7) 1
Low–high 129 8.4 (7.7–9.1) 0.524 (0.391–0.702) <0.001 17.8 (16.9–18.7) 0.522 (0.371–0.771) <0.001
High–low 151 8.2 (7.8–8.6) 0.733 (0.636–0.846) <0.001 17.0 (15.6–18.4) 0.837 (0.699–1.003) 0.053
High–high 121 10.6 (9.8–11.4) 0.631 (0.566–0.702) <0.001 22.2 (21.0–23.4) 0.636 (0.562–0.719) <0.001
Fig. 2 Kaplan–Meier estimates of progression‑free and overall survival of patients with newly diagnosed metastatic colorectal cancer according to 
the changes in LMR before and after chemotherapy. a progression‑free survival, b overall survival
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whose LMR remained low (low–low subgroup) after 
chemotherapy. A recent study evaluated the prognostic 
impact of the neutrophil-to-lymphocyte ratio (NLR) in 
199 non-smokers with advanced lung adenocarcinoma 
receiving gefitinib or standard chemotherapy as first-
line therapy [25]. In the high pre-treatment NLR group, 
patients whose NLR decreased after treatment had a 
longer OS than those whose NLR remained high follow-
ing treatment (20.7 vs. 7.9 months, P < 0.001). Similarly, 
in the low pre-treatment NLR group, patients whose 
NLR remained low after treatment had a longer OS than 
those whose NLR increased after treatment (26.4 vs. 
18.9 months, P < 0.001) [25]. Therefore, a change in LMR 
before and after chemotherapy seemed to predict the 
benefit of chemotherapy in chemotherapy-naïve mCRC 
patients receiving the FOLFOX regimen.
The strengths of this study are the large sample size 
and the relatively low heterogeneity of patients who 
were all diagnosed with chemotherapy-naïve mCRC and 
treated with FOLFOX chemotherapy. Nevertheless, the 
major limitation of this study is its retrospective design, 
which contributes to selection bias. Prospective stud-
ies are necessary to validate our results. Additionally, 
inflammatory factors such as lymphocytes and mono-
cytes may be influenced by many potential confound-
ing factors, such as latent infection and autoimmune 
disease. Hence, potential confounding factors must be 
excluded while considering LMR as a prognostic factor 
for cancer patients.
In conclusion, for patients with previously untreated 
mCRC receiving FOLFOX chemotherapy, a high pre-chem-
otherapy LMR is an independent favorable prognostic fac-
tor for PFS and OS, and changes in LMR before and after 
chemotherapy seem to predict the benefit of chemotherapy.
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